Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Jason Aldred; Eric Freire-Alvarez; Alexander V. Amelin; Angelo Antonini; Bruno Bergmans; Filip Bergquist; Manon Bouchard; Kumar Budur; Camille Carroll; K. Ray Chaudhuri; Susan R. Criswell; Erik H. Danielsen; Florin Gandor; Jia Jia; Thomas E. Kimber; Hideki Mochizuki; Weining Z. Robieson; Amy M. Spiegel; David G. Standaert; Saritha Talapala; Maurizio F. Facheris; Victor S.C. Fung

doi:10.1007/s40120-023-00554-w

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Jason Aldred^*
, Eric Freire-Alvarez
, Alexander V. Amelin
, Angelo Antonini
, Bruno Bergmans
, Filip Bergquist
, Manon Bouchard
, Kumar Budur
, Camille Carroll
, K. Ray Chaudhuri
, Susan R. Criswell
, Erik H. Danielsen
, Florin Gandor
, Jia Jia
, Thomas E. Kimber
, Hideki Mochizuki
, Weining Z. Robieson
, Amy M. Spiegel
, David G. Standaert
, Saritha Talapala

Maurizio F. Facheris, Victor S.C. Fung

^*Corresponding author for this work

Peninsula Medical School

Selkirk Neurology and Inland Northwest Research
Hospital General Universitario de Elche
Pavlov First State Medical University of St. Petersburg
University of Padua
General Hospital St. Jan
Ghent University
University of Gothenburg
Clinique Neuro-Lévis
AbbVie
King's College London
Washington University St. Louis
Aarhus University
Movement Disorders Hospital
Otto von Guericke University Magdeburg
Royal Adelaide Hospital
University of Adelaide
Osaka University
University of Alabama at Birmingham
University of Sydney
Westmead Hospital

Research output: Other contribution › peer-review

31 Downloads (Pure)

Original language	English
DOIs	https://doi.org/10.1007/s40120-023-00554-w
Publication status	Published - 10 Oct 2023

Access to Document

10.1007/s40120-023-00554-w

Correction Continuous Subcutaneous FoslevodopaFoscarbidopa in Parkinsons Disease Safety and Efficacy Results From a 12-Month

Cite this

Aldred, J., Freire-Alvarez, E., Amelin, A. V., Antonini, A., Bergmans, B., Bergquist, F., Bouchard, M., Budur, K., Carroll, C., Chaudhuri, K. R., Criswell, S. R., Danielsen, E. H., Gandor, F., Jia, J., Kimber, T. E., Mochizuki, H., Robieson, W. Z., Spiegel, A. M., Standaert, D. G., ... Fung, V. S. C. (2023, Oct 10). Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. https://doi.org/10.1007/s40120-023-00554-w

@misc{b77ac91884e84e1c8d9ada31bc1a8c1f,

title = "Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson{\textquoteright}s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study",

author = "Jason Aldred and Eric Freire-Alvarez and Amelin, \{Alexander V.\} and Angelo Antonini and Bruno Bergmans and Filip Bergquist and Manon Bouchard and Kumar Budur and Camille Carroll and Chaudhuri, \{K. Ray\} and Criswell, \{Susan R.\} and Danielsen, \{Erik H.\} and Florin Gandor and Jia Jia and Kimber, \{Thomas E.\} and Hideki Mochizuki and Robieson, \{Weining Z.\} and Spiegel, \{Amy M.\} and Standaert, \{David G.\} and Saritha Talapala and Facheris, \{Maurizio F.\} and Fung, \{Victor S.C.\}",

year = "2023",

month = oct,

day = "10",

doi = "10.1007/s40120-023-00554-w",

language = "English",

type = "Other",

}

Aldred, J, Freire-Alvarez, E, Amelin, AV, Antonini, A, Bergmans, B, Bergquist, F, Bouchard, M, Budur, K, Carroll, C, Chaudhuri, KR, Criswell, SR, Danielsen, EH, Gandor, F, Jia, J, Kimber, TE, Mochizuki, H, Robieson, WZ, Spiegel, AM, Standaert, DG, Talapala, S, Facheris, MF & Fung, VSC 2023, Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. https://doi.org/10.1007/s40120-023-00554-w

TY - GEN

T1 - Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

AU - Aldred, Jason

AU - Freire-Alvarez, Eric

AU - Amelin, Alexander V.

AU - Antonini, Angelo

AU - Bergmans, Bruno

AU - Bergquist, Filip

AU - Bouchard, Manon

AU - Budur, Kumar

AU - Carroll, Camille

AU - Chaudhuri, K. Ray

AU - Criswell, Susan R.

AU - Danielsen, Erik H.

AU - Gandor, Florin

AU - Jia, Jia

AU - Kimber, Thomas E.

AU - Mochizuki, Hideki

AU - Robieson, Weining Z.

AU - Spiegel, Amy M.

AU - Standaert, David G.

AU - Talapala, Saritha

AU - Facheris, Maurizio F.

AU - Fung, Victor S.C.

PY - 2023/10/10

Y1 - 2023/10/10

UR - https://pearl.plymouth.ac.uk/pms-research/399/

U2 - 10.1007/s40120-023-00554-w

DO - 10.1007/s40120-023-00554-w

M3 - Other contribution

ER -

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Access to Document

Other files and links

Cite this